Benzinga's Top Downgrades
Analysts at Piper Jaffray downgraded MAKO Surgical (NASDAQ: MAKO) from “overweight” to “neutral.” The target price for MAKO Surgical has been raised from $26 to $30. MAKO Surgical's shares closed at $29.70 yesterday.
Analysts at Barclays downgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from “overweight” to “underweight.” The target price for ARIAD Pharmaceuticals has been lowered from $25 to $4. ARIAD Pharmaceuticals' shares closed at $5.83 yesterday.
Nomura downgraded Maxim Integrated Products (NASDAQ: MXIM) from “buy” to “neutral.” The target price for Maxim Integrated Products is set to $28. Maxim Integrated's shares closed at $29.22 yesterday.
Analysts at Ascendiant Capital downgraded Leapfrog Enterprises (NYSE: LF) from “buy” to “neutral.” The target price for Leapfrog Enterprises has been lowered from $12 to $8. Leapfrog's shares closed at $9.15 yesterday.
Latest Ratings for MAKO
Date | Firm | Action | From | To |
---|---|---|---|---|
Oct 2013 | Downgrades | Overweight | Neutral | |
Sep 2013 | Downgrades | Buy | Neutral | |
Sep 2013 | Downgrades | Outperform | Market Perform |
View More Analyst Ratings for MAKO
View the Latest Analyst Ratings
Posted-In: Top DowngradesDowngrades Analyst Ratings
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.